AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks

Press/Media: Press / Media

PeriodAug 3 2017 → Aug 9 2017

Media coverage

5

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date8/9/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date8/8/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date8/7/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPredictWallStreet
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPR Distribution
    CountryPoland
    Date8/3/17
    PersonsFred Poordad